The Apple Watch 13, set to debut in 2027, is rumored to be the first model equipped with blood sugar monitoring capabilities. This feature has been in development for several years, as indicated by reports dating back to the Apple Watch Series 7 released in 2021. At that time, there were claims that Apple was on the verge of launching a blood sugar monitoring system.
However, those promises did not materialize, and in 2024, Apple was reportedly testing a related app for health data collection rather than for public use. Analyst Jeff Pu has recently claimed that blood sugar monitoring will be a pivotal feature of the Apple Watch Series 13. He suggested that this model might be marketed as “Apple Watch featuring Blood Monitoring.”
Unfortunately, details about the feature remain scarce. Pu has shared timelines for this development, but it is unclear whether his insights are based on supply chain information or derived from previous analyses related to Apple’s product roadmap. While Pu has occasionally provided accurate forecasts, he also has a track record of announcing release schedules that often prove to be incorrect.
Despite this, Apple continues to enhance the health features of its Watch lineup, such as the inclusion of blood oxygen level monitoring. However, this technology has faced challenges, including a patent dispute, and is currently disabled on Apple Watches sold in the United States. It’s essential to note that Apple is not alone in the pursuit of non-invasive blood sugar monitoring technology.
In January 2025, PreEvnt showcased a clip-on device that uses breath analysis to track blood glucose levels, demonstrating the growing interest in this field among technology companies. As the timeline for the Apple Watch 13 approaches, many are eager to see how these advancements unfold.
Leave a Reply